5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1409-1411

  Breccia, Massimo ^a   Salaroli, Adriano ^a   Loglisci, Giuseppina ^a   Martelli, Maurizio ^a   D'Elia, Gianna Maria ^a   Nanni, Mauro ^a   Mauro, Francesca Romana ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Azacitine; Efficacy; Therapy related MDS

Indexed keywords

AZACITIDINE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLAST CELL; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; CANCER CLASSIFICATION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CHROMOSOME ANALYSIS; CYTOPENIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; HEART FAILURE; HUMAN; KARYOTYPE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 80052091577     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.030     Document Type: Article

References (8)

1. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 10:1389-1398.
2. Bathia R., Deeg H.J. Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. Curr Opin Hematol 2011, 18:77-82.
3. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 15:2429-2440.
4. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. International Vidaza High-risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 2009, 10:223-232.
5. Andre M., Mounier N., Leleu X., Sonet A., Brice P., Henry-Amar M., et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin Lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004, 103:1222-1228.
6. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A.G., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407-1427.
7. Carney D.A., Westerman D.A., Tam C.S., Milner A., Prince H.M., Kenealy M., et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010, 24:2056-2062.
8. Itzykson R., Thepot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.